In contemporary clinical oncology practice and drug development, the methods for evaluating tumor response are on the cusp of a revolution. Since the World Health Organization (WHO) proposed tumor response classification criteria for assessing the effectiveness of anti-cancer drugs in 1981, this field has undergone several improvements. Notably, th...

Transcriptomic Analysis of Prostate Cancer Patients: A Study on Nonlocalized Disease Based on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Academic Background Prostate cancer is a common male malignancy, and its diagnosis and treatment are crucial to patient prognosis. Transcriptomic analysis is a technique us...

Overall Survival and Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Patients Based on PTEN Status Academic Background Prostate cancer is one of the most common malignant tumors among men worldwide and a leading cause of cancer-related deaths. Approximately 10%-20% of prostate cancer patients will develop castration-resistant ...

In the tumor microenvironment (Tumor Microenvironment, TME), Immune Checkpoint Inhibitors (ICIs) targeting PD-1 or PD-L1 enhance the body’s natural ability to eliminate cancer cells by disrupting the inhibitory receptor-ligand interaction. However, even so, critical trials indicate that the response rate for monotherapy is <50%, with a median Progr...

Ovarian cancer is one of the most common and deadly tumor types in women. In recent years, Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown encouraging clinical results in the treatment of ovarian cancer. Numerous studies have found that patients with homologous recombination deficiency (HRD) benefit more from PARPi treatment. Therefore, ...